# A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Lupus Nephritis

> **NCT02256150** · PHASE3 · COMPLETED · sponsor: **Asahi Kasei Therapeutics Corporation** · enrollment: 250 (actual)

## Conditions studied

- Lupus Nephritis

## Interventions

- **DRUG:** Mizoribine (MZR)
- **DRUG:** Cyclophosphamide (CTX)

## Key facts

- **NCT ID:** NCT02256150
- **Lead sponsor:** Asahi Kasei Therapeutics Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2019-03
- **Final completion:** 2019-03
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2019-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02256150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02256150, "A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Lupus Nephritis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02256150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*